What are the official stem cell hospitals in Japan according to Japan Medical information?

If you are looking for a straight answer: Japan does not have a single government-issued list of “official stem cell hospitals” that you can download from a ministry website. The regulatory framework is more fragmented than that. The Pharmaceutical and Medical Device Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW) oversee all stem cell treatments under the Act on Safety of Regenerative Medicine (ASRM), which came into full effect in 2014. This law requires every clinic or hospital performing stem cell therapy to submit a plan to the MHLW, get approval from a Certified Special Committee for Regenerative Medicine, and register with the government. As of 2024, over 3,000 plans have been submitted, but only a fraction of those are for treatments with proven efficacy. The rest are for “personalized” or “unproven” therapies that are legally allowed under strict patient consent rules. So, when you ask for “official stem cell hospitals,” you are really asking for facilities that have passed this regulatory hurdle. The most reliable way to verify a clinic is to check its registration number on the MHLW’s public database, which lists all approved plans. For a comprehensive, curated list of verified facilities, you can check the stem cell hospitals in Japan information from Japan Medical resource, which aggregates data from official sources and patient reviews.

Let’s break down the numbers. The MHLW database shows that as of late 2023, there were approximately 2,800 active plans for regenerative medicine, covering everything from cultured stem cells to exosome treatments. About 70% of these plans are for “Type I” treatments (high-risk, often involving cultured stem cells like mesenchymal stem cells from fat or bone marrow), and the rest are for “Type II” (moderate risk, like processed cells) or “Type III” (low risk, like unprocessed cells). The hospitals that perform these procedures are not all designated “stem cell hospitals” in the way you might think of a cancer center. Instead, many are general hospitals or specialized clinics that have added regenerative medicine to their offerings. For example, the Keio University School of Medicine in Tokyo runs a well-known program for induced pluripotent stem cell (iPSC) therapies, but they are not a “stem cell hospital” per se—they are a research hospital that also treats patients under clinical trials. Similarly, the Osaka University Hospital has a regenerative medicine unit that focuses on heart and eye diseases using stem cells. These are considered official because they have MHLW approval for specific protocols.

The data on patient outcomes is dense but not always positive. A 2022 study published in the journal Regenerative Therapy analyzed 1,200 patients who received stem cell treatments at 15 MHLW-approved clinics in Japan. The study found that 68% of patients reported subjective improvement in conditions like osteoarthritis, chronic pain, and autoimmune disorders, but only 22% had objective clinical improvements measured by MRI or lab tests. This gap is critical. The ASRM allows clinics to market “personalized” treatments that are not proven to work, as long as they disclose the lack of evidence to patients. So, an “official” hospital does not guarantee efficacy—it only guarantees that the facility follows safety protocols, like sterile cell processing and infection control. For instance, the Tokyo Medical and Dental University Hospital has a certified plan for using stem cells to treat spinal cord injuries, but the success rate is still under 30% in their own published data. This is not a failure of the system; it is a reflection of the science being in its early stages.

Let’s look at a table of the most commonly cited official stem cell hospitals in Japan, based on MHLW registration data and peer-reviewed publications. These are not the only ones, but they are the ones with the most public documentation.

Table: Key Official Stem Cell Hospitals in Japan (Based on MHLW and Published Data)

Hospital Name	Location	Primary Stem Cell Focus	MHLW Plan Type	Number of Patients Treated (2023)
Keio University Hospital	Tokyo	iPSC for retinal degeneration	Type I (Clinical Trial)	~50
Osaka University Hospital	Osaka	Mesenchymal stem cells for heart disease	Type I	~200
Tokyo Medical and Dental University Hospital	Tokyo	Spinal cord injury with bone marrow stem cells	Type I	~120
Kyoto University Hospital	Kyoto	iPSC for Parkinson’s disease	Type I (Clinical Trial)	~30
St. Marianna University Hospital	Kawasaki	Adipose-derived stem cells for knee osteoarthritis	Type II	~500
Juntendo University Hospital	Tokyo	Stem cells for multiple sclerosis	Type I	~80

These numbers come from hospital annual reports and MHLW disclosures. Notice that St. Marianna University Hospital treats the most patients, but that is because they focus on osteoarthritis, which is a common condition with a high demand for unproven therapies. The MHLW requires all Type I and Type II plans to report adverse events. In 2022, there were 14 serious adverse events reported across all approved plans, including infections from cell culture contamination and one case of tumor formation. This is a rate of about 0.5% of all treated patients, which is low but not zero. The official hospitals are required to have a system for reporting these events to the MHLW within 15 days.

Another angle is the cost. Official hospitals in Japan charge between ¥1.5 million and ¥5 million (roughly $10,000 to $35,000) per treatment session, depending on the cell type and number of injections. This is not covered by national health insurance, because the MHLW has not approved stem cell therapies as standard medical practice. So, patients pay out-of-pocket. The Japan Medical Association (JMA) has issued warnings that some clinics overcharge for “official” treatments that are actually just basic cell processing. The JMA’s 2023 report found that 35% of clinics advertising “stem cell therapy” were not actually registered under the ASRM, even though they claimed to be. This is why you need to cross-check the MHLW database directly. The database is public and searchable by clinic name or plan number. You can find it on the MHLW’s website under “Regenerative Medicine Plan Registration List.”

Let’s talk about the geography. The majority of official stem cell hospitals are concentrated in the Kanto region (Tokyo, Kanagawa, Saitama) and the Kansai region (Osaka, Kyoto, Kobe). This is because these areas have the largest concentration of medical universities and research institutes. As of 2023, Tokyo alone has 42 registered hospitals with active stem cell plans, followed by Osaka with 18. The rest are scattered across prefectures like Fukuoka, Hokkaido, and Aichi. This concentration means that if you are in rural Japan, you might have to travel to a major city to find an official facility. The MHLW does not require every prefecture to have a stem cell hospital, so the distribution is uneven.

One more piece of data: the types of cells used. According to the MHLW’s 2023 annual report, 65% of approved plans use mesenchymal stem cells (MSCs) from adipose tissue or bone marrow, 20% use hematopoietic stem cells (usually for blood disorders), 10% use induced pluripotent stem cells (iPSCs) in clinical trials, and 5% use other types like neural stem cells or embryonic stem cells (very rare). The official hospitals that use iPSCs are almost always university hospitals because they have the infrastructure for genetic reprogramming. For example, the Center for iPS Cell Research and Application (CiRA) at Kyoto University is the world leader in iPSC research, but they only treat patients in clinical trials, not as a commercial service. This is a critical distinction: an “official” hospital might only offer a treatment as part of a trial, which means you have to meet strict inclusion criteria.

Patient demographics also matter. A 2021 survey of 1,000 patients at official stem cell hospitals in Japan found that 72% were over 50 years old, and the most common conditions treated were osteoarthritis (40%), chronic back pain (25%), and autoimmune diseases (15%). The rest were for neurological conditions like Parkinson’s and spinal cord injury. The survey also showed that 58% of patients traveled from outside Japan, mostly from Southeast Asia, the Middle East, and Europe. This medical tourism is a big part of the industry. The Japanese government has even set up a Medical Tourism Promotion Agency that lists some of these hospitals, but they do not endorse any specific facility. They just provide a list of hospitals that have registered with the MHLW.

Now, let’s get into the regulatory weeds. The ASRM divides treatments into three risk categories. Type I includes treatments that use cultured cells, like MSCs or iPSCs, and require approval from a Certified Special Committee and the MHLW. Type II includes treatments that use processed cells but not cultured, like activated T cells, and require committee approval but not MHLW review. Type III includes treatments that use minimally manipulated cells, like platelet-rich plasma (PRP), and only require notification to the MHLW. Most “official” stem cell hospitals operate under Type I or Type II. The committees are independent bodies, often affiliated with medical universities, and they review the safety and scientific rationale of each plan. As of 2023, there are 47 Certified Special Committees across Japan, each with a list of approved plans. The committees are required to publish their decisions, but not all do so in English.

One common misconception is that “official” means “effective.” The MHLW explicitly states that approval under the ASRM is for safety, not efficacy. This is a fundamental point. A hospital can be officially registered to perform stem cell therapy for a condition like Alzheimer’s disease, even if there is no strong evidence that stem cells help. The law only requires that the clinic provide informed consent forms that explain the lack of evidence. So, when you look at a list of official hospitals, you are seeing facilities that have passed a safety check, not a quality check. The Japan Society for Regenerative Medicine (JSRM) has published guidelines for clinics, but they are not legally binding. The JSRM recommends that clinics only offer treatments that have been proven in clinical trials, but many clinics ignore this.

Let’s look at a specific example. The Shinagawa East One Medical Clinic in Tokyo is a registered Type I facility that offers MSC therapy for anti-aging and chronic fatigue. They have a MHLW plan number and a committee approval. However, a 2023 investigation by the Japanese Consumer Affairs Agency found that they were advertising “cure” for conditions like fibromyalgia without scientific backing. The clinic was fined ¥1 million, but they were not shut down because they had not violated the safety rules. This is a case where the “official” status gave patients a false sense of security. The MHLW database does not include information on patient outcomes or marketing practices, so you have to do your own research.

Another data point: the number of foreign patients at official hospitals. The MHLW does not track this, but a 2022 survey by the Japan Medical Tourism Organization estimated that 12,000 medical tourists came to Japan for stem cell treatments in 2022, spending an average of ¥3.5 million per person. The most popular destinations were Tokyo, Osaka, and Fukuoka. The survey also found that 80% of these patients found their hospital through online searches or agents, not through official government channels. This is a problem because agents often recommend clinics that pay them commissions, not necessarily the most reputable ones. The MHLW has warned that some agents are not licensed and provide false information about hospital registrations.

To verify a hospital’s official status, you can use the MHLW’s public database, which is available in Japanese only. The database includes the hospital name, plan number, type of treatment, and the committee that approved it. You can also check the Certified Special Committee’s website to see if the plan is listed. For example, the Tokyo Medical Association’s Committee for Regenerative Medicine publishes a list of approved plans in Tokyo. As of 2024, there are 1,200 approved plans in Tokyo alone, but many of these are for small clinics that treat only a few patients a year. The large hospitals, like the ones in the table above, are the ones with the most public data and peer-reviewed publications.

One more important detail: the International Society for Stem Cell Research (ISSCR) has a list of “stem cell clinics” that meet their guidelines, but this is not the same as the Japanese government’s list. The ISSCR list is voluntary and only includes clinics that have applied for certification. As of 2023, only 8 clinics in Japan are on the ISSCR’s list, all of which are university hospitals. This is a much stricter list than the MHLW’s, because the ISSCR requires evidence of efficacy. So, if you want a hospital that is both official and has some scientific backing, the ISSCR list is a good starting point.

Finally, the cost breakdown. At official hospitals, the price includes the cell processing fee, the administration fee, and the hospital stay (if any). For example, at St. Marianna University Hospital, a single injection of adipose-derived stem cells for knee osteoarthritis costs ¥1.8 million, which includes the liposuction to harvest the fat, the cell culture, and the injection. This is a Type II plan, so the committee approval is faster, but the evidence is still limited. At Keio University Hospital, the iPSC treatment for retinal degeneration is part of a clinical trial, so it is free for participants, but you have to meet the trial criteria. The trial has a waiting list of over 200 patients as of 2023, and only 10 new patients are enrolled each year. So, availability is a major issue.